About
Ciprofloxacin and Celecoxib combo
Areas of Focus
Categories
Middle East
Team (16)
Board Member
Dr. Revital Mandil-Levin
NeuroSense Therapeutics
team_member
CEO & Board Member
Alon Ben-Noon
NeuroSense Therapeutics
team_member
Chairman of the board
Mark Leuchtenberger
NeuroSense Therapeutics
team_member
Chief Financial Officer
Or Eisenberg
NeuroSense Therapeutics
team_member
Chief Medical Officer
Dr. Ferenc Tracik
NeuroSense Therapeutics
team_member
Chief Technology Officer
Dr. Niva Russek-Blum
NeuroSense Therapeutics
team_member
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
146
By Phase
PHASE2: 3PHASE1: 3
By Status
COMPLETED: 5RECRUITING: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06185543Lead Sponsor
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.
PHASE2Recruiting
20 participants
Started: Nov 19, 2023 · Completed: Nov 30, 2025
NCT05436678Lead Sponsor
A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject
PHASE1Completed
19 participants
Started: Jul 26, 2022 · Completed: Oct 20, 2022
NCT05357950Lead Sponsor
A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
PHASE2Completed
69 participants
Started: May 31, 2022 · Completed: Nov 4, 2024
NCT05232461Lead Sponsor
A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects
PHASE1Completed
12 participants
Started: Apr 8, 2022 · Completed: Aug 30, 2022
NCT04090684Lead Sponsor
Ciprofloxacin/Celecoxib Combination in Patients With ALS
PHASE1Completed
10 participants
Started: Dec 9, 2019 · Completed: Jan 20, 2022
Locations (1)
Headquarters
Herzliya, Israel
Map
Loading map...